Filtered By:
Source: Thrombosis and Haemostasis
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 528 results found since Jan 2013.
Immunity in Stroke: The Next Frontier
Thromb Haemost. 2022 Jun 10. doi: 10.1055/s-0042-1748890. Online ahead of print.ABSTRACTTranslational stroke research has long been focusing on neuroprotective strategies to prevent secondary tissue injury and promote recovery after acute ischemic brain injury. The inflammatory response to stroke has more recently emerged as a key pathophysiological pathway contributing to stroke outcome. It is now accepted that the inflammatory response is functionally involved in all phases of the ischemic stroke pathophysiology. The immune response is therefore considered a breakthrough target for ischemic stroke treatment. On one side,...
Source: Thrombosis and Haemostasis - June 10, 2022 Category: Hematology Authors: Ting Li Arthur Liesz Source Type: research
Point of Care Assessment of Direct Oral Anticoagulation in Acute Ischemic Stroke: Protocol for a Prospective Observational Diagnostic Accuracy Study
This study will test the hypothesis that hyperacute point-of-care assessment of clotting time in the patient's whole blood has sufficient diagnostic accuracy to determine immediately whether stroke patients are pretreated with DOAC. Methods/ Design: This will be a prospective single-center diagnostic accuracy study in 1850 consecutive acute ischemic stroke patients at a tertiary stroke center in Saxony, Germany. Presence of active anticoagulation with DOAC will be determined by point-of-care quantification of clotting time via whole blood viscoelastic testing (ClotPro®) using Russell venom viper and Ecarin assay compared ...
Source: Thrombosis and Haemostasis - June 7, 2022 Category: Hematology Authors: Annahita Sedghi Lars Heubner Anna Klimova Oliver Tiebel J örg Pietsch Martin Mirus Kristian Barlinn Tabea Tabita Talita Tatjana Minx Jan Beyer-Westendorf Volker Puetz Peter Spieth Timo Siepmann Source Type: research
Ischemic Stroke with Cancer: Hematologic and Embolic Biomarkers and Clinical Outcomes
CONCLUSIONS: Markers of hypercoagulability and embolic disease may be associated with adverse clinical outcomes in cancer-related stroke.PMID:35652416 | DOI:10.1111/jth.15779
Source: Thrombosis and Haemostasis - June 2, 2022 Category: Hematology Authors: Babak B Navi Cenai Zhang Carla P Sherman Richard Genova Natalie M LeMoss Hooman Kamel Scott T Tagawa Ashish Saxena Allyson J Ocean Scott E Kasner Mary Cushman Mitchell S V Elkind Ellinor Peerschke Lisa M DeAngelis Source Type: research
Clopidogrel monotherapy versus Aspirin monotherapy in patients with established cardiovascular disease: systematic review and meta-analysis
CONCLUSIONS: In patients with established cardiovascular disease, Clopidogrel was associated with a 17% relative-risk reduction for non-fatal MI, borderline decreased risk for MACE and similar risk for all-cause mortality, stroke and major bleeding compared to Aspirin.PMID:35577054 | DOI:10.1055/a-1853-2952
Source: Thrombosis and Haemostasis - May 16, 2022 Category: Hematology Authors: Panagiotis Tasoudis Ioannis Kyriakoulis Dimitrios Sagris Hans-Christoph Diener George Ntaios Source Type: research
Early rhythm control and the risks of ischaemic stroke, heart failure, mortality and adverse events when performed early ( & lt;3 months)
CONCLUSIONS: Early rhythm control, especially when performed earlier (<3months), was associated with a lower risk of adverse events than usual care among patients with early AF.PMID:35322396 | DOI:10.1055/a-1807-0336
Source: Thrombosis and Haemostasis - March 24, 2022 Category: Hematology Authors: Tze-Fan Chao Yi-Hsin Chan Chern-En Chiang Ta-Chuan Tuan Jo-Nan Liao Tzeng-Ji Chen Gregory Yh Lip Shih-Ann Chen Source Type: research
Effectiveness and safety of apixaban vs. rivaroxaban in patients with atrial fibrillation and type 2 diabetes mellitus
CONCLUSIONS: Among patients with NVAF and T2DM, apixaban was associated with a similar risk of stroke, and a lower risk of major bleeding compared with rivaroxaban.PMID:35292949 | DOI:10.1055/a-1798-2116
Source: Thrombosis and Haemostasis - March 16, 2022 Category: Hematology Authors: Krishna Roy Chowdhury Jonathan Michaud Oriana Hoi Yun Yu Hui Yin Laurent Azoulay Christel Renoux Source Type: research
JAK2V617F Is a Risk Factor for TIA/Stroke in Young Patients
The objective of this study was to assess the risk of arterial thrombosis in patients who harbor the JAK2V617F allele burden ≥1% detected during workup for myeloproliferative neoplasms (MPNs). We conducted a large cross-sectional analysis consisted of 5,220 patients who were tested for JAK2V617F and 1,047,258 people matched in age from health care insurance provider, taking into account age, sex, hypertension, diabetes, atrial fibrillation. Compared with noncarriers, mutation carriers were older, less likely to be current or past smokers and had lower body mass index. There was no significant difference between the group...
Source: Thrombosis and Haemostasis - March 15, 2022 Category: Hematology Authors: Tamar Shapira Cohen Gabriel Chodick David M Steinberg Ehud Grossman Mordechai Shohat Ophira Salomon Source Type: research
Multi-phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations
CONCLUSIONS: The discovery of 4 novel loci contributes to the understanding of the relationship between hemostasis and CV events and elucidate common genetic factors between these traits.PMID:35285134 | DOI:10.1111/jth.15698
Source: Thrombosis and Haemostasis - March 14, 2022 Category: Hematology Authors: Gerard Temprano-Sagrera Colleen M Sitlani William P Bone Miguel Martin-Bornez Benjamin F Voight Alanna C Morrison Scott M Damrauer Paul S de Vries Nicholas L Smith Maria Sabater-Lleal Source Type: research
